Pasithea Therapeutics (KTTA) Current Assets (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Current Assets for 4 consecutive years, with $9.8 million as the latest value for Q3 2024.
- Quarterly Current Assets fell 52.92% to $9.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Sep 2024, down 52.92% year-over-year, with the annual reading at $16.7 million for FY2023, 51.02% down from the prior year.
- Current Assets hit $9.8 million in Q3 2024 for Pasithea Therapeutics, up from $8.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $53.3 million in Q4 2021 to a low of $8.6 million in Q2 2024.
- Historically, Current Assets has averaged $29.3 million across 4 years, with a median of $28.0 million in 2023.
- Biggest five-year swings in Current Assets: soared 111.42% in 2022 and later tumbled 69.17% in 2024.
- Year by year, Current Assets stood at $53.3 million in 2021, then tumbled by 36.07% to $34.1 million in 2022, then tumbled by 51.02% to $16.7 million in 2023, then crashed by 41.42% to $9.8 million in 2024.
- Business Quant data shows Current Assets for KTTA at $9.8 million in Q3 2024, $8.6 million in Q2 2024, and $13.2 million in Q1 2024.